BRIEF published on 05/08/2026 at 22:35, 4 months 3 days ago Integrated BioPharma annonce une baisse de son chiffre d'affaires trimestriel Résultats Financiers Perte Nette Baisse Des Revenus Perte D'exploitation Fabrication Sous Contrat
BRIEF published on 05/08/2026 at 22:35, 4 months 3 days ago Integrated BioPharma Reports Decrease in Quarterly Revenue Financial Results Revenue Decline Net Loss Operating Loss Contract Manufacturing
PRESS RELEASE published on 05/08/2026 at 22:30, 4 months 3 days ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 Integrated BioPharma, Inc. reports $10.1M revenue for Q1 2026, a 27.3% decrease from Q1 2025. Operating loss of $1.1M in Q1 2026. Financial summary provided Financial Results Revenue Quarterly Report Operating Loss Integrated BioPharma
BRIEF published on 02/11/2026 at 22:35, 7 months ago Integrated BioPharma annonce ses résultats financiers du quatrième trimestre 2025 Résultats Financiers Perte Nette Baisse Des Revenus Perte D'exploitation Dépendance Du Client
BRIEF published on 02/11/2026 at 22:35, 7 months ago Integrated BioPharma Announces Q4 2025 Financial Results Financial Results Revenue Decline Net Loss Operating Loss Customer Dependency
PRESS RELEASE published on 02/11/2026 at 22:30, 7 months ago Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025 Integrated BioPharma, Inc. reports financial results for Q4 2025, showing a $1.3M decrease in revenue and operating loss compared to Q4 2024. Key financial details provided Financial Results Revenue Decrease Operating Loss Integrated BioPharma Quarterly Performance
BRIEF published on 11/10/2025 at 21:55, 10 months 1 day ago Integrated BioPharma publie ses résultats financiers pour le troisième trimestre 2025 Résultats Financiers Baisse Des Revenus Résultat D'exploitation Revenu Net Fabrication Sous Contrat
BRIEF published on 11/10/2025 at 21:55, 10 months 1 day ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 10 months 1 day ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 11 months 18 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
Published on 09/12/2026 at 02:35, 11 hours 1 minute ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 36 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 31 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 11 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 36 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 6 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 21 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 26 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 51 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 21 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
